Opinion

Video

Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, durability of response, and management of brain metastases.

Panel Introduction

CROWN Trial and Lorlatinib Treatment in ALK+ Metastatic NSCLC

  • Discussion focused on the 5-year data from the CROWN trial evaluating lorlatinib for ALK-positive metastatic NSCLC
  • Analysis of how these long-term outcomes have influenced the current treatment paradigm
  • Comparison of clinical trial results with real-world outcomes observed by treating physicians

Key Treatment Considerations

  • Long-term survival benefits and durability of response with lorlatinib
  • Emphasis on efficacy against brain metastases, which are common in ALK+ NSCLC
  • Cost-effectiveness evaluations when selecting frontline treatment options

Clinical Implementation

  • Real-world efficacy and safety profile of lorlatinib compared to clinical trial results
  • Practical considerations in implementing treatments based on CROWN trial evidence
  • Balance between efficacy outcomes and economic considerations in treatment decisions

Notable Insights

  • Dr. Dietrich was asked to describe the CROWN trial design and elaborate on how the 5-year data has influenced the treatment landscape for ALK+ metastatic NSCLC, particularly regarding survival outcomes and response durability.
  • Dr. Lovly addressed the unique long-term outcomes with lorlatinib, especially its efficacy against brain metastases, and discussed the complex balance between cost considerations and clinical efficacy when making frontline treatment decisions.
  • Castronovo provided perspective on real-world clinical experience with lorlatinib, comparing observed efficacy and safety profiles with those reported in the controlled CROWN trial setting.
Related Videos
4 experts are featured in this series.
1 expert in this video
4 experts are featured in this series.
1 expert in this video
1 expert is featured in this series.
5 experts in this video
Dr Mingyang Song
Dr Samantha Garcia
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo